Acute flaccid myelitis (AFM) presents significant challenges not only to patients but also to researchers, and efforts must be accelerated to learn more about the condition, experts from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, write in a new perspective published in mBio.

Enterovirus-D68 Image/CDC
Enterovirus-D68
Image/CDC

AFM is a condition associated with a recent infection, including those caused by polioviruses or non-polio enteroviruses, that causes sudden muscle paralysis. Polioviruses were once the major causes of AFM but now account for almost no cases because polio is nearly eradicated worldwide. There is no vaccine to prevent non-polio AFM, and no specific treatment is currently available to cure the condition. However, evidence indicates that early intensive physical therapy, which has helped patients with polio improve, may benefit other AFM patients, and should be considered as early as possible for children with AFM symptoms, according to the authors.

The authors note that the term AFM was coined in recent years, but the condition itself represents a subset of cases of a long-recognized syndrome called acute flaccid paralysis. AFM unexpectedly re-emerged globally in epidemic form in 2014 and appears to occur at the same time and locations as outbreaks of the once-obscure enterovirus-D68 (EV-D68), which causes respiratory illness that is typically mild, and EV-A71, another enterovirus. Experts have yet to prove definitively that EV-D68 is a major cause of epidemic AFM. However, the epidemiological evidence implicating the virus is growing, the authors explain.

Read more at NIH